HomeFull speed ahead. Keep track of advancements in every frontier

TheTechno Optimist.

PAI-1 inhibitorJuvenescence—

PAI-1 inhibitor

by JuvenescenceGB

ProtoStage 2 of 5

First trial done; Phase 2 in metabolic and scarring diseases planned for 2026.

Updated Jan 2026Checked 25 Sep0 updates this week

Milestones

Next · Phase 2 starts
  1. First trial completedJan 2026Complete.
  2. Phase 2 startsTarget 2026Current milestone.

Most important updates

  • Jan 2026
  • 21 Mar 2022

Upcoming

  1. 2026Phase 2 starts (next)

Physics limits

  • PAI-1 also stops bleedingPAI-1 keeps clots from dissolving too early. People with no working PAI-1 have a bleeding disorder, so a drug can only lower it partly, not remove it.
  • The genetic clue comes from one small groupThe lifespan link rests on 177 people from one Amish community. A drug taken in adulthood may not match a lifelong genetic change.
  • Old scar tissue is slow to reverseScarring diseases build stiff collagen over years. Blocking a driver can slow new scarring, but existing scar tissue clears slowly, if at all.

How it works

3 parts
A blood clot in an electron microscope: red cells caught in fibrin mesh; PAI-1 blocks the enzymes that dissolve clots like this
A blood clot in an electron microscope: red cells caught in fibrin mesh; PAI-1 blocks the enzymes that dissolve clots like thisPhoto: Janice Carr · Public domain (opens commons.wikimedia.org)
Target

PAI-1 rises with age

PAI-1 stops the body's clot-dissolving enzymes. Levels climb with age, obesity and scarring diseases, and worn-out cells release lots of it.

Genetics

A natural experiment

Amish carriers of one broken PAI-1 gene have about half the normal level and lived about 10 years longer in a 2017 study.

Drug

A daily pill to lower it

MDI-2517, a small molecule, blocks PAI-1 to mimic that half-loss; Phase 1 found it safe with once-daily dosing.

Update log

2 updates

Jan 2026

  • Minor: PressTest

Mon 21 Mar 2022

  • Minor: PressCommercial

About Juvenescence

The team behind PAI-1 inhibitor

Juvenescence

Longevity drugs, PAI-1 blocker

UK-based longevity biotech co-founded in 2017 by investor Jim Mellon. It makes drugs for aging-linked diseases (scarring, heart and metabolic, brain, inflammation), led by a pill that blocks PAI-1.

  • Its PAI-1 blocker finished its first trial in Jan 2026 as a once-a-day pill; a Phase 2 test is planned for later in 2026.
  • Abu Dhabi health group M42 invested and partnered on AI drug discovery in Jul 2026.

juvlabs.com (opens juvlabs.com)Company profile →

Founded
20179 yrs
Headquarters
United Kingdom
Status
Private
Valuation
private
Works in
LongevityAnti-aging drugs
Coverage
1 program · 5 updateslatest 1 Jan 2026checked 25 Sep
Investors
M42 (opens m42.ae)
People
Jim Mellon (opens en.wikipedia.org)Co-founder
Primer